Condition (MeSH)
Cutaneous Fistula
ClinicalTrials.gov lists 2 trials for Cutaneous Fistula or a narrower condition beneath it. Coloplast A/S has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Cutaneous Fistula itself; the rest are tagged with a narrower condition beneath it.
When did Cutaneous Fistula trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2016 | 1 |
| 2006 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cutaneous Fistula trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2/3 | 1 |
| Not applicable | 1 |
How many Cutaneous Fistula trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cutaneous Fistula trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Coloplast A/S | 1 |
Which publications cover Cutaneous Fistula? (43)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Use of Cervical Fascia to Prevent Pharyngocutaneus Fistula After Total Laryngectomy. | The Laryngoscope | 2024 | Yes |
| Endoscopic management of refractory leak and gastro-cutaneous fistula after laparoscopic sleeve gastrectomy: a randomized controlled trial. | Surgical endoscopy | 2023 | Yes |
| Platelet-rich fibrin: an autologous biomaterial for healing assistance of pharyngeal repair in total laryngectomy. | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | 2021 | Yes |
| Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection. | Inflammatory bowel diseases | 2020 | Yes |
| Risk factors of pharyngocutaneous fistula after total laryngectomy: a systematic review and meta-analysis. | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | 2020 | Yes |
Showing 5 of 43 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.